NEW YORK (GenomeWeb) – Protea Biosciences Group today said that it has signed an agreement to collaborate with the University of Southampton to identify biomarkers that may indicate a risk of developing Alzheimer's disease.

Researchers will use Protea's direct molecular imaging technology and capabilities to study the molecular mechanisms of the aged brain in an effort to identify the markers. Protea researchers, led by Matthew Powell and Greg Kilby, will collaborate with a team of Alzheimer's researchers at the University of Southampton led by Roxana Carare.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Jul
12
Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.